MedTrace Logo

Efficacy and Safety of Benvitimod Cream in the Retreatment of Mild to Moderate Psoriasis

NCT05326659 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 390

Last updated 2022-04-13

No results posted yet for this study

Summary

This is a retreatment, multicenter, randomized, double-blind, placebo-controlled clinical study to evaluate the safety and efficacy of Benvitimod cream, 1% twice daily for the retreatment of mild to moderate stable psoriasis vulgaris in adults. Approximately 390 participants with mild to moderate stable psoriasis vulgaris will be enrolled and randomly divided into two groups in a 2:1 ratio. They will use either the Benvitimod cream or placebo at the skin with psoriasis vulgaris for 12 weeks.

Conditions

Interventions

DRUG

Benvitimod Cream

Benvitimod cream, 1%, applied twice daily for 12 weeks after enrolment.

DRUG

Placebo

Placebo, applied twice daily for 12 weeks after enrolment.

Sponsors & Collaborators

  • Zhonghao Pharmaceutical

    collaborator UNKNOWN

  • Peking University People's Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-30
Primary Completion
2023-06-30
Completion
2023-08-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05326659 on ClinicalTrials.gov